PAR-22-249: Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $2.0 million to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on January 6, 2023.
From the official notice on Grants.gov, last changed October 26, 2022. Checked November 7, 2026.
- Award ceiling$2.0 million
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU54
- Clinical trialsOptional
- Funded byNCI
- Median yearly award$157,550
- Typical project length10 years
- U54, Specialized Center Cooperative Agreement. A research center with several projects and shared cores, with substantial NIH involvement. Other open U54 notices.
Projects funded under PAR-22-249 were run by National Cancer Institute (NCI, 13 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-22-249 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-23-308 | October 5, 2023 | Closed February 21, 2025 | Closed |
Key dates
| Posted | October 26, 2022 |
|---|---|
| Deadline | January 6, 2023 |
| Archived by Grants.gov | February 11, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $157,550; it allows up to $2.0 million per award.
- Most of the money in the 7 programs behind this notice (63% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This funding opportunity seeks to support the Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) Program. The CPACHE Program develops and maintains comprehensive, long-term, and mutually beneficial partnerships between institutions serving underserved health disparity populations and underrepresented students (ISUPSs) and NCI-designated Cancer Centers (CCs). The program aims to achieve a more robust national cancer program and address challenges in cancer and cancer disparities research, education, and outreach, as well as their impact on underserved populations. The institutions in each partnership are expected to work collaboratively to 1) increase the cancer research and cancer research education capacity of the ISUPSs; 2) increase the number of students and investigators from underrepresented populations engaged in cancer research; 3) improve the effectiveness of CCs in developing and sustaining research programs focused on cancer health disparities and increase the number of investigators and students conducting cancer health disparities research, and 4) develop and implement cancer-related activities that benefit the surrounding underserved communities.
Funded under PAR-22-249 so far
NIH funded 13 projects under PAR-22-249 in fiscal 2023 to 2026, at 13 institutions. The median yearly award was $157,550.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| 2/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch | Fred Hutchinson Cancer Center | 2026 | $1.4 million |
| Outreach Core | New Mexico State University Las Cruces | 2026 | $133,959 |
| Capacity Development Core | University of California Riverside | 2026 | $222,569 |
| Research Education Core | Temple Univ of the Commonwealth | 2026 | $310,965 |
| Biostatistics and Bioinformatics Core (BBC) | Hunter College | 2026 | $73,039 |
| Pilot Project 6 | University of Florida | 2026 | $172,445 |
| Tissue Modeling and Drug Development Core (TMDDC) Shared Resource | University of Southern California | 2026 | $108,501 |
| Shared Resource Core: Quantitative Sciences Core | H. Lee Moffitt Cancer Ctr & Res Inst | 2026 | $163,459 |
Who has won Cancer Treatment Research grants before
From fiscal 2021 to 2025, Cancer Treatment Research (93.395) awarded $5.6 billion across 3,622 grant awards, an average of $1.5 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 144 | $188 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 68 | $185 million |
| Icahn School of Medicine at Mount Sinai | New York | 35 | $179 million |
| Public Health Institute | California | 4 | $168 million |
| Fred Hutchinson Cancer Center | Washington | 57 | $156 million |
Who has won Cancer Biology Research grants before
From fiscal 2021 to 2025, Cancer Biology Research (93.396) awarded $4.3 billion across 3,142 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of Columbia University in the City of New York | New York | 70 | $151 million |
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 109 | $144 million |
| Sloan-Kettering Institute for Cancer Research | New York | 66 | $136 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 47 | $107 million |
| The Regents of the University of California, San Francisco | California | 64 | $95.5 million |
Who has won Cancer Cause and Prevention Research grants before
From fiscal 2021 to 2025, Cancer Cause and Prevention Research (93.393) awarded $3.6 billion across 2,517 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 81 | $107 million |
| Sloan-Kettering Institute for Cancer Research | New York | 65 | $99.1 million |
| The Trustees of Columbia University in the City of New York | New York | 48 | $85.3 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 51 | $83.1 million |
| University of North Carolina at Chapel Hill | North Carolina | 49 | $76.1 million |
Other programs behind this notice
- Cancer Centers Support Grants
- Cancer Detection and Diagnosis Research
- Cancer Research Manpower
- Cancer Control
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-22-249 still open?
No. It closed on January 6, 2023.
Who can apply for Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional)?
Closed January 6, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $2.0 million each.
Who has been funded under PAR-22-249?
NIH RePORTER lists 13 projects funded under PAR-22-249 in fiscal 2023 to 2026, at 13 institutions. The most were at Fred Hutchinson Cancer Center, New Mexico State University Las Cruces, University of California Riverside.
Who has won Cancer Cause and Prevention Research grants before?
The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York. The program made 2,517 awards worth $3.6 billion in that time.
Similar open grants
- Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) (U54 Clinical Trial Optional)
- Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required)
- Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)
- Health and Extreme Weather Solutions-Focused Research Hubs (U54 - Clinical Trial Optional)
- George M. O’Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional)
- Limited Competition: The NHGRI Analysis, Visualization, and Informatics Lab-space (AnVIL) (U54 Clinical Trial Not Allowed)